Artiva Biotherapeutics, Inc. ARTV Exchange Offer (Note 12)
Exchange Offer (Note 12) at other companies
Other financials
Where this comes from
Reported directly by Artiva Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ConversionOfStockAmountConverted1.
The official record: Artiva Biotherapeutics, Inc.’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →
Ask your AI about Artiva Biotherapeutics, Inc.'s exchange offer (note 12).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Artiva Biotherapeutics, Inc.'s exchange offer (note 12)?
- Artiva Biotherapeutics, Inc. (ARTV) reported exchange offer (note 12) of $0 in Q4 2025.
- How has Artiva Biotherapeutics, Inc.'s exchange offer (note 12) changed year-over-year?
- Artiva Biotherapeutics, Inc.'s exchange offer (note 12) decreased by 100.0% year-over-year, from $54.1M to $0.
- What does exchange offer (note 12) mean?
- Captures the non-cash value of debt or other securities converted into common stock as part of an exchange offer or restructuring. This activity reflects changes in the company's capital structure and the reduction of liabilities through equity issuance.